Skip to content
Clinical ResearchResearch compound

SANA (MVD‑1)

Experimental anti-obesity compound that does not curb appetite but boosts heat production in fat tissue; not yet approved.

SANA (MVD-1) vial

DETAILED OVERVIEW

What is SANA (MVD-1)?

SANA (MVD-1) is an experimental drug candidate from Eolo Pharma, now in clinical-stage development, aimed at obesity. Unlike the appetite-reducing drugs common today, such as GLP-1 drugs, it does not curb hunger but tries to raise energy expenditure by boosting heat production in fat tissue. Neither the US nor the European regulator has approved it, and it is not available on the open research-chemical market, so products offered online under the name SANA are unreliable.

It works by switching on a “wasteful” creatine cycle in beige fat, a type of fat tissue able to produce heat: the cell burns energy that is released as heat. This pathway is well studied, but SANA’s own human data are still emerging, so its effectiveness and safety are not proven. There is no public human data on its side effects or on its effects on the liver, kidneys and heart. It must not be used in pregnancy or breastfeeding, because there is no safety data. In competitive sport it may count as banned, because it is an unapproved investigational substance.

Mechanism

Activation of creatine-dependent thermogenesis ('futile creatine cycle') in thermogenic / beige fat – raises energy expenditure, NOT an appetite suppressant

Developer / code

Eolo Pharma; development code MVD1. Clinical-stage, first-in-human program published.

Half-life

NOT public (clinical-stage compound; human PK data not publicly available)

Onset

NOT publicly known (human efficacy still emerging in the first-in-human program)

Legal status

Investigational, NOT approved (neither FDA nor EMA). Not on the open research-chemical market the way older compounds are.

Data console

Lab data

Androgenic:AnabolicN/A (not AAS, but a small molecule targeting creatine-dependent thermogenesis)
AR bindingNo public quantitative binding-affinity data for SANA…
Active half-lifeNOT public (clinical-stage compound; human PK data not publicly available)
Detection windowNo publicly validated, WADA-accredited detection protocol exists for SANA (investigational compound). In a competitive-sport context, the assessment would be interpreted under the 'S0 catch-all' category.
AromatizationDoes not aromatize – not a steroid, but a small molecule targeting creatine-dependent thermogenesis. No CYP19 interaction.
HepatotoxicityUnknown / emerging – clinical-stage compound; long-term human safety is NOT established. Detailed public human liver-safety data are not available; the assessment depends on the unfolding of Eolo Pharma's first-in-human program.

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • No published human side-effect profile: an investigational clinical-phase compound, so the specific nature and frequency of effects are unknown.
  • Theoretical mechanism-based risk: raising thermogenesis (heat production) could in principle increase warmth sensation, sweating or alter resting metabolism, this is NOT confirmed human data.
  • Unknown hepatic and renal impact: no public human liver or kidney safety data exists, clearance and organ burden are uncharacterized.
  • Unknown cardiovascular and thermoregulatory effect: no public human PK/PD, so cardiac, blood-pressure and heat-regulation effects are unassessed.
  • Unknown interaction and additive risk with other metabolism-activating agents (MOTS-c, BAM15, SLU-PP-915, ATX-304); no clinical data on combinations.
  • Product-safety risk: SANA is not on the open market, so any product sold online as 'SANA' has unverifiable contents and is unreliable.

Contraindications · 6

  • Human self-medication in general: an investigational, NOT approved (neither FDA nor EMA) compound with no approved human dose or protocol, use outside a supervised clinical trial is contraindicated.
  • Pregnancy and breastfeeding: absolute contraindication, no human reproductive safety data.
  • Known liver or kidney disease: human clearance and organ burden are unknown, contraindicated.
  • Cardiovascular disease: no human cardiovascular safety data for an energy-expenditure-raising mechanism, contraindicated.
  • Competitive athletes: the WADA 'S0 catch-all non-approved substance' category may potentially apply to a non-approved, investigational agent.
  • Concurrent use with other metabolism-activating / thermogenic agents: additive and interaction effects are unknown, caution advised (relative contraindication).

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about SANA (MVD‑1)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.